The impact of thalidomide on immune checkpoints in dendritic cells

Dendritic cells (DCs) effectively break down and transmit antigens to modulate the immune response. Dendritic cells (DCs) may activate or inhibit antigen-specific T lymphocytes. Thalidomide, a sedative, was withdrawn due to its tendency to induce congenital malformations. Anti-inflammatory and anti-angiogenic properties help this medicine suppress the immune system. This research examines how thalidomide affects immunological checkpoint gene expression in monocyte-derived dendritic cells. Thalidomide disrupts multiple cellular signaling pathways and is known to regulate the immune system. MACS was used to isolate monocytes from peripheral blood mononuclear cells (PBMCs) after the Ficoll process. GM-CSF and IL-4 were applied to monocytes in 6-well plates. After that, the plate was put in a 0C37 incubator and checked daily for contamination. On day three, half of the wells' medium was gradually replaced with cytokine-containing media. After flow cytometry measurement of mo-DC differentiation, thalidomide was given. To evaluate thalidomide therapy, flow cytometry was used to investigate mo-DC phenotype. Real-time PCR was performed to measure immune genes associated with different checkpoints in mo-DC groups that got therapy and those that did not. The research found that thalidomide increased CD86 and HLA-DR expression in dendritic cells after administration. Thus, it may affect dendritic cell growth and function markers. After thalidomide injection, dendritic cells (DCs) had lower levels of the immunological checkpoints LAG3 and VISTA. These cells have more B and T-lymphocyte attenuators (BTLA). This experiment suggests that thalidomide may target DC cells and change their properties.